Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389519 · ClinicalTrials.gov registry record · Phase 3
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 422
- Enrollment target
NCT00389519: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00389519 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 422 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00389519, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 422 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.
Primary Outcome
Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo
Interventions
- DRUG placebo
- DRUG ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Why NCT00389519 stopped before completion
NCT00389519 is an interventional study that assigns participants to a tested intervention. The registered 422 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00389519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00389519 about?
NCT00389519 is a clinical study titled "A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents". The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.
What is the current status of trial NCT00389519?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2006-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00389519?
The interventions under investigation include: placebo (DRUG), ramipril (DRUG).
Who is sponsoring clinical trial NCT00389519?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00389519's enrollment target sits among peer trials
422 886th of 2000 higher than 1,111 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT06837246 · 422 participants · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
- NCT07298967 · 422 participants · NA
ORCHARDS-AIR Study
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia